US FDA Expands In-Person Meeting Eligibility, But So Far No Takers

virtual meeting
Pre-ANDA product development and ANDA pre-submission meetings join Type A and Biosimilar Product Development Type 1 meetings as eligible for the hybrid format. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics